학술논문
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Document Type
Article
Author
Source
In The Lancet Oncology May 2015 16(5):509-521
Subject
Language
ISSN
1470-2045